Periodic Reporting for period 1 - RESCBONE (The influence of mechanical loading on the decline in bone mass with ageing)
Reporting period: 2015-04-01 to 2017-03-31
Osteoporosis is an age and sex-related condition characterised by reduced bone mass, impaired micro-architecture and increased risk of low-trauma fractures. Osteoporosis-related fractures are a major health concern (occurring in 45 percent of Caucasian females and 13 percent of males) and impose a huge economic burden on health care systems. Bone mass and architecture in young people are normally adjusted to be able to withstand loading without fracture through a process of adaptation to functional loading. Osteoporosis represents a failure of this regulation particularly evident in women. We have shown in mice that their anabolic response to short periods of increased load-bearing is also impaired in an age and sex-related manner. Counter-intuitively, this response can be “rescued” in old female mice if short periods of loading are imposed against a background of disuse rather than normal activity. This “rescue” has not yet been demonstrated in males. We hypothesise from our other studies that the “lesion” in old mice, that appears to be “rescued” by concurrent disuse, involves reduced recruitment of osteoblasts (Ob). The primary objective of RESCBONE was to establish whether the age and sex-related decline in bones’ adaptive response to loading in mice can be located to a deficiency in the recruitment of the osteoblasts necessary to form new bone and, if so, whether it is this deficiency that can be rescued by appropriate manipulation of bone’s total loading experience.
Loading results in site-specific increases in the number of bone forming osteoblast cells. Interestingly, it has not been possible to detect any increase in cell proliferation at the sites of bone formation before the increase in osteoblast cell number can be detected after a period of loading. It is thus unknown from where these new osteoblasts come. Using mice that overexpress fluorescent proteins in specific cells of interest, we have now identified the origin of some of the osteoblasts at the most actively bone forming regions at the bone surface. Interestingly, these cells cannot account for all the cells found on these surfaces, so the mechanosensitive bone forming osteoblasts must also originate from other sites than the periosteum.
Parathyroid hormone (PTH) is, when given intermittently (iPTH) the only bone anabolic drug currently in clinical use. Wefound that in aged, as in young mice, iPTH is osteogenic in cortical bone but, unlike in young mice, it acts independently of the mechanostat (the ability of bone to sense mechanical load). In trabecular bone, iPTH does not have the dramatic osteogenic effect seen in young mice and appears to reduce the positive effects of mechanical loading on trabecular number. The mechanism of this age-related dissociation of the effects of iPTH and mechanical loading needs to be determined.
There are several putative osteoporosis treatments currently in clinical trials. One of them, an antibody against sclerostin, is believed to be bone anabolic in humans as it is in rodents. Sclerostin inhibits Wnt16, an important contributor to bone formation, controlling bone mass and fracture risk, and is downregulated by loading. Taken together this led us to investigate whether Wnt16 expression is regulated by age, sex, loading/unloading and oestrogen treatment (previously a common treatment for osteoporosis). Our findings suggest that while Wnt16 is not an obligatory contributor to regulation of bone mass per se, it potentially plays a role in influencing pathways associated with regulation of bone mass during ageing and oestrogen withdrawal.
Bisphosphonates are the first line treatments for osteoporosis world-wide today. We have studied old female mice and can show that, as in young mice, the osteogenic effects of loading in aged mice is primarily via bone modelling (only bone formation altering bone shape and architecture), rather than remodelling (both bone formation and resorption, not affecting shape or architecture).
We extended this study to investigate the effect of risedronate on disuse mediated rescue of the blunted loading response in old female mice. There was a site specific response to the combined treatment with risedronate, disuse and load, and we conclude that the rescue of the anabolic response to load in old mice can be further improved by co-treatment with risedronate. To the extent that this could be extrapolated to the human situation, exercise management in combination with bisphosphonate treatment could improve bone formation in the old.
Within RESCBONE, we have also investigated the combination of iPTH-treatment and loading, which are anabolic, with risedronate which is an anti-resorptive agent. Our preliminary data show that iPTH and risedronate site-specifically further enhance bone mass in response to load. Thus, the bone anabolic effects of loading seem to be stronger when it is combined with the two different drugs.
RESCBONE clarifies further steps in the understanding of the process of bone building which are necessary in the creation of an effective treatment for osteoporosis and thus prevention of osteoporosis-related fractures. The project has shown that the magnitude of the osteogenic response to load, and the local site within the bone where new bone is formed, is different depending on sex and age. Interestingly, the age-dependent decline in loading response can, at least partly, be restored in both males and females when applied on a background of disuse. Our finding that α-SMA positive cells on the periosteal bone surface proliferate and differentiate into osteoblasts in response to load, sheds light on a new cell-type involved in bones’ natural anabolic responses to loading that could be a potential target for new osteogenic drugs for treating bone fragility disorders such as osteoporosis. Common osteoporosis treatments, together with loading, result in further beneficial effects on bone mass and possibly bone strength. Thus, if our data can be extrapolated to the human situation, appropriate exercise management, could enhance the beneficial effects of osteoporosis treatments such as PTH or bisphosphonates and thus further prevent recurrent osteoporotic fractures. This could also be of particular relevance in maintaining bone mass in situations of paralysis or even space flight.